Pharmala Biotech Holdings Inc. (CSE:MDMA)

Pharmala Biotech Holdings Balance Sheet

Financials in millions CAD. Fiscal year is September - August.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb 28, 2026	Aug 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021
Cash & Equivalents	0.11	0.04	0.42	0.2	0.85	2.47
Short-Term Investments	0.46	0.92	-	-	-	-
Cash & Short-Term Investments	0.58	0.96	0.42	0.2	0.85	2.47
Cash Growth	-61.75%	129.07%	115.02%	-77.11%	-65.53%	-
Accounts Receivable	0.38	0.02	0.16	0.12	0.02	-
Other Receivables	0.03	0.04	0.05	0.1	0.03	0.06
Receivables	0.42	0.06	0.21	0.22	0.05	0.06
Inventory	0.39	0.37	0.35	0.12	0.12	-
Prepaid Expenses	0	0.25	0.06	0.17	0.07	-
Total Current Assets	1.39	1.65	1.04	0.71	1.09	2.53
Property, Plant & Equipment	0	0	0	0	0	0
Other Intangible Assets	1.74	1.77	1.85	1.7	1.24	0.26
Total Assets	3.13	3.42	2.9	2.41	2.33	2.79
Accounts Payable	0.45	0.56	0.52	0.48	0.35	0.11
Accrued Expenses	-	-	0.03	0.1	0.02	0.03
Current Unearned Revenue	0.52	0.4	0.37	0.19	0.05	-
Other Current Liabilities	-	-	-	0.25	-	-
Total Current Liabilities	0.97	0.96	0.92	1.03	0.42	0.14
Total Liabilities	0.97	0.96	0.92	1.03	0.42	0.14
Common Stock	7.82	7.45	5.69	5.14	4.83	0.08
Additional Paid-In Capital	0.99	0.91	0.86	0.38	0.38	0.14
Retained Earnings	-7.88	-7.13	-4.96	-4.13	-3.49	-2.51
Comprehensive Income & Other	1.23	1.23	0.38	-	0.19	4.94
Shareholders' Equity	2.16	2.46	1.98	1.38	1.91	2.66
Total Liabilities & Equity	3.13	3.42	2.9	2.41	2.33	2.79
Net Cash (Debt)	0.58	0.96	0.42	0.2	0.85	2.47
Net Cash Growth	-61.75%	129.07%	115.02%	-77.11%	-65.53%	-
Net Cash Per Share	0.01	0.01	0.00	0.00	0.01	0.08
Filing Date Shares Outstanding	108.89	108.89	94.29	84.98	83	83
Total Common Shares Outstanding	108.92	106.6	91.72	86.08	83	42.31
Working Capital	0.41	0.69	0.13	-0.32	0.66	2.39
Book Value Per Share	0.02	0.02	0.02	0.02	0.02	0.06
Tangible Book Value	0.41	0.69	0.13	-0.31	0.67	2.4
Tangible Book Value Per Share	0.00	0.01	0.00	-0.00	0.01	0.06
Machinery	-	-	-	0.01	0.01	0

Source: S&P Global Market Intelligence. Standard template. Financial Sources.